From Fatigued to Fantastic!

by Jacob Teitelbaum

  47. W. Jefferies, “Cortisol and Immunity,” Medical Hypotheses 1991; 34: 198–208.

  48. Riccardo Baschetti, “Investigations of Hydrocortisone and Fludrocortisone in the Treatment of Chronic Fatigue Syndrome,” Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 6, 2263–2264.

  49. R. A. Anderson et al., “Chromium and Hypoglycemia,” abstract, American Journal of Clinical Nutrition 41 (4) (April 1985): 841.

  50. W. M. Jefferies, “Low-Dosage Glucocorticoid Therapy: An Appraisal of Its Safety and Mode of Action in Clinical Disorders, Including Rheumatoid Arthritis,” Archives of Internal Medicine 119 (3) (March 1967): 265–278.

  51. R. McKenzie, A. O’Fallon, J. Dale, et al., “Low-Dose Hydrocortisone for Treatment of Chronic Fatigue Syndrome: A Randomized Controlled Trial,” Journal of the American Medical Association 280 (12) (23–30 September 1998): 1061–1066.

  52. J. E. Teitelbaum, B. Bird, A. Weiss, et al., “Low Dose Hydrocortisone for Chronic Fatigue Syndrome,” Journal of the American Medical Association 281 (1999): 1887–1888.

  53. A. J. Cleare, E. Heap, G. S. Malhi, et al., “Low-Dose Hydrocortisone in CFS: A Randomized Crossover Trial,” The Lancet 353 (9151) (6 February 1999): 455–458.

  54. A. Cleare et al., “Hypothalamo-Pituitary-Adrenal Axis Dysfunction in Chronic Fatigue Syndrome, and the Effects of Low-Dose Hydrocortisone Therapy,” Journal of Clinical Endocrinology & Metabolism 2001; 86 (8): 3545–3554.

  55. J. A. Da Silva, J. W. Jacobs, J. R. Kirwan, M. Boers, K. G. Saag, L. B. Ines, E. J. de Koning, F. Buttgereit, M. Cutolo, H. Capell, R. Rau, J. W. Bijlsma, “Safety of Low Dose Glucocorticoid Treatment in Rheumatoid Arthritis: Published Evidence and Prospective Trial Data,” Ann Rheum Dis. 2006 March; 65 (3): 285–293, E-published August 17, 2005.

  56. Principles and Practice of Endocrinology and Metabolism, 3rd ed., Kenneth Becker, ed. (Philadelphia: Lippincott, Williams & Wilkins, 2001).

  57. P. M. J. Zelissen, R. J. Croughs, P. P. van Rijk, et al., “Effect of Glucocorticoid Replacement Therapy on Bone Mineral Density in Patients with Addison Disease,” Annals of Internal Medicine 120 (3) (1 February 1994): 207–210.

  58. A. Susmano, A. S. Volgman, and T. A. Buckingham, “Beneficial Effects of DextroAmphetamine in the Treatment of Vasodepressor Syncope,” Pacing and Clinical Electrophysiology 16 (1993): 1235–1239.

  59. B. P. Grubb, D. A. Wolfe, D. Samoil, et al., “Usefulness of Fluoxetine Hydrochloride for Prevention of Resistant Upright Tilt Induced Syncope,” Pacing and Clinical Electrophysiology 16 (1993): 458–464.

  60. B. P. Grubb, D. Samoil, D. Kosinski, et al., “Use of Sertraline Hydrochloride in the Treatment of Refractory Neurocardiogenic Syncope in Children and Adolescents,” Journal of the American College of Cardiology 24 (1994): 490–494.

  61. P. C. Rowe, I. Bou-Holaigah, J. S. Kan, et al., “Is Neurally Mediated Hypotension an Unrecognized Cause of Chronic Fatigue?” The Lancet 345 (8950) (11 March 1995): 623–624.

  62. O. Ozerbil, N. Okudan, H. Gokbel, and F. Levendoglu, “Comparison of the Effects of Two Antidepressants on Exercise Performance of the Female Patients with Fibromyalgia,” Clin Rheumatol 2005 November 3: 1–3 (E-published ahead of print).

  63. D. Blockmans, P. Persoons, B. van Houdenhove, and H. Bobbaers, “Does Methylphenidate Reduce the Symptoms of Chronic Fatigue Syndrome?” Am J Med 2006 February; 119 (2): 167.

  64. A. W. Meikle, R. A. Daynes, B. A. Araneo, et al., “Adrenal Androgen Secretion and Biologic Effects,” Endocrine and Metabolic Clinics of North America 20 (2) (June 1991): 381–421.

  65. L. N. Parker, “Control of Adrenal Androgen Secretion,” Endocrine and Metabolic Clinics of North America 20 (2) (June 1991): 401–421.

  66. E. Barrett-Connor, R. T. Khaw, and S. C. Yen, “A Prospective Study of DHEA, Mortality and Cardiovascular Disease,” New England Journal of Medicine 315 (1986): 1519–1524.

  67. M. L. Lydic, M. McNurlan, et al., “Chromium Picolinate Improves Insulin Sensitivity in Obese Subjects with Polycystic Ovary Syndrome,” Fertil Steril, 2006; 86 (1): 243–246.

  68. G. R. Skinner, R. Thomas, M. Taylor, et al., “Thyroxine Should Be Tried in Clinically Hypothyroid but Biochemically Euthyroid Patients,” British Medical Journal 314 (7096) (14 June 1997): 1764.

  69. G. R. B. Skinner, D. Holmes, A. Ahmad, et al., “Clinical Response to Thyroxine Sodium in Clinically Hypothyroid but Biochemically Euthyroid Patients,” Journal of Nutritional and Environmental Medicine 10 (2) (June 2000): 115–125.

  70. R. A. Nordyke, T. S. Reppun, L. D. Madanay, et al., “Alternative Sequences of Thyrotropin and Free Thyroxine Assays for Routine Thyroid Function Testing: Quality and Cost,” Archives of Internal Medicine 158 (3) (9 February 1998): 266–272.

  70A.L. Hallberg, “Does Calcium Interfere with Iron Absorption?” editorial, American Journal of Clinical Nutrition 68 (1) (July 1998): 3–4.

  71. J. G. Travell and D. G. Simons, Myofascial Pain and Dysfunction: The Trigger Point Manual, Vol. 1 (Baltimore, MD: Williams & Wilkins, 1983), pp. 103–164.

  72. J. C. Lowe, R. L. Garrison, A. J. Reichman, et al., “Effectiveness and Safety of T3 Therapy for Euthyroid Fibromyalgia: A Double-Blind, Placebo-Controlled Response Driven Crossover Study,” Clinical Bulletin of Myofascial Therapy 2 (2/3) (1997): 31–58.

  73. J. C. Lowe, A. J. Reichman, and J. Yellin, “The Process of Change During T3 Treatment for Euthyroid Fibromyalgia: A Double-Blind, Placebo-Controlled, Crossover Study,” Clinical Bulletin of Myofascial Therapy 2 (2/3) (1997): 91–124.

  74. E. Vliet, Screaming to Be Heard: Hormonal Connections Women Suspect…and Doctors Ignore (New York: M. Evans and Co., 2001).

  75. T. G. Travison, A. B. Araujo, A. B. O’Donnell, et al., “A Population-Level Decline in Serum Testosterone Levels in American Men,” J Clin Endocrin Metab, first published ahead of print October 24, 2006 as doi: 10.1210.

  76. http://www.dartmouth.edu/~news/releases/2003/april/040703a.html

  77. Unpublished data from our research center.

  78. http://www.medscape.com/viewarticle/544182

  79. H. Burger, “How Effective Is Testosterone Replacement Therapy in Premenopausal Women with Severe Androgen Deficiency?” Nat Clin Pract Endocrinol Metab. 2006; 2 (8): 432–433.

  80. http://www.medscape.com/viewarticle/544182

  81. H. Burger, “How Effective Is Testosterone Replacement Therapy in Premenopausal Women with Severe Androgen Deficiency?” Nat Clin Pract Endocrinol Metab. 2006; 2 (8): 432–433.

  82. Shores, M Arch Intern Med 2006; 166: 1660–1665.

  83. http://www.medscape.com/viewarticle/543797

  84. http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11034937

  85. http://www.ncbi.nlm.nih.gov/entrez/ query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8222891

  86. E. Rhoden, BJU International 2005; 98: 867–870.

  87. C. J. Malkin, “Testosterone Therapy in Men with Moderate Severity Heart Failure: A Double-Blind Randomized Placebo Controlled Trial,” Eur Heart J, 2006; 27 (1): 57–64, 44567 (4/2006).

  88. C. C. Carson, “Prostate Cancer: Is Testosterone Replacement Therapy a Safety Issue?” Medical Clinics of North America, 90 (1) September 2006, 23–27.

  89. C. S. Cooper, P. J. Perry, A. E. Sparks, J. H. MacIndoe, W. R. Yates, R. D. Williams, “Effect of Exogenous Testosterone on Prostate Volume, Serum and Semen Prostate Specific Antigen Levels in Healthy Young Men,” J Urol 1998 February; 159 (2): 441–443.

  90. O. N. Pamuk and N. Cakir, “The Variation in Chronic Widespread Pain and Other Symptoms in Fibromyalgia Patients: The Effects of Menses and Menopause,” Clin Exp Rheumatol 2005 November-December; 23 (6): 778–782.

  91. J. S. Jenkins, “The Role of Oxytocin: Present Concepts,” Clinical Endocrinology 34 (1991): 515–525.

  92. M. L. Vance, “Hypopituitarism,” New England Journal of Medicine 330 (23) (9 June 1994): 1651–1662.

  93. S. Pillemer, L. A. Bradley, L. J. Crofford, et al., �
�The Neuroscience and Endocrinology of FMS—[An NIH] Conference Summary,” Arthritis and Rheumatism 40 (11) (November 1997): 1928–1939.

  94. A. M. O. Bakheit, P. O. Behan, W. S. Watson, et al., “Abnormal Arginine-Vasopressin Secretion and Water Metabolism in Patients with Postviral Fatigue Syndrome,” Acta Neurologica Scandinavica 87 (3) (March 1993): 234–238.

  95. P. C. Rowe, H. Calkins, K. DeBusk, et al., “Fludrocortisone Acetate to Treat Neurally Mediated Hypotension in Chronic Fatigue Syndrome: A Randomized Controlled Trial,” Journal of the American Medical Association 285 (1) (3 January 2001): 52–59.

  ARTICLE ON SAFETY OF BIOIDENTICAL HORMONES AT THE END OF CHAPTER 4

  1. H. J. Chang and T. T. Y. Lee, et al., “Influences of Percutaneous Administration of Estradiol and Progesterone on Human Breast Epithelial Cell Cycle in Vivo,” Fertil Steril 1995; 63: 785–791.

  2. L. A. Fitzpatrick et al. “Comparison of Regimens Containing Oral Micronized Progesterone of Medroxyprogesterone Acetate on Quality of Life in Postmenopausal Women: A Cross-Sectional Survey,” J Womens Health Gen Based Med 2000 May; 9(4): 381–387.

  3. Gompel et al. “Antiestrogen Action of Progesterone in Breast Tissue,” Breast Cancer Res Treat 1986; 8 (3): 179–188.

  4. Van der Burg et al. “Effects of Progestins on the Proliferation of Estrogen-Dependent Human Breast Cancer Cells Under Growth Factor-defined Conditions,” J Steroid Biochem Mol Biol 1992 June; 42 (5): 457–465.

  5. J. A. Mol, E. van Garderen, G. R. Rutteman, and A. Rijnberk, “New Insights in the Molecular Mechanism of Progestin-Induced Proliferation of Mammary Epithelium: Induction of the Local Biosynthesis of Growth Hormone (GH) in the Mammary Glands of Dogs, Cats and Humans,” J Steroid Biochem Mol Biol 1996 January; 57 (1–2): 67–71.

  6. B. S. Hulka, “Links Between Hormone Replacement Therapy and Neoplasia,” Fertil Steril 1994 December; 62 (6 supplement 2): 168S–175S.

  7. L. J. Hofseth, A. M. Raafat, J. R. Osuch, D. R. Pathak, C. A. Slomski, and S. Z. Haslam, “Hormone Replacement Therapy with Estrogen or Estrogen Plus Medroxyprogesterone Acetate Is Associated with Increased Epithelial Proliferation in the Normal Postmenopausal Breast.” J Clin Endocrinol Metab 1999 December; 84 (12): 4559–4565.

  8. J. M. Foidart, C. Colin, X. Denoo, J. Desreux, A. Beliard, S. Fournier, and B. de Lignieres, “Estradiol and Progesterone Regulate the Proliferation of Human Breast Epithelial Cells,” Fertil Steril 1998 May; 69 (5): 963–969.

  9. G. A. Colditz and B. Rosner, “Cumulative Risk of Breast Cancer to Age 70 Years According to Risk Factor Status: Data from the Nurses’ Health Study,” Am J Epidemiol 2000 November 15; 152 (10): 950–964.

  10. R. K. Ross, A. Paganini-Hill, P. C. Wan, and M. C. Pike, “Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin,” J Natl Cancer Inst 2000 February 16; 92 (4): 328–332.

  12. “Estrogen Replacement Therapy and Heart Disease: A Discussion of the PEPI Trial,” Women’s Health Information Center.

  13. K. Miyagawa, J. Rosch, F. Stanczyk, and K. Hermsmeyer, “Medroxyprogesterone Interferes with Ovarian Steroid Protection Against Coronary Vasospasm,” Nat Med 1997 March; 3 (3): 324–327.

  14. G. M. Rosano, C. M. Webb, S. Chierchia, G. L. Morgani, M. Gabraele, P. M. Sarrel, D. de Ziegler, and P. Collins, “Natural Progesterone, but not Medroxyprogesterone Acetate, Enhances the Beneficial Effect of Estrogen on Exercise-Induced Myocardial Ischemia in Postmenopausal Women,” J Am Coll Cardiol 2000 December; 36 (7): 2154–2159.

  15. T. B. Clarkson, “Progestogens and Cardiovascular Disease: A Critical Review,” J Reprod Med 1999 February; 44 (2 supplement): 180–184.

  16. W. E. Feeman, “Thrombotic Stroke in an Otherwise Healthy Middle-aged Female Related to the Use of Continuous-Combined Conjugated Equine Estrogens and Medroxyprogesterone Acetate,” J Gend Specif Med 2000 November-December; 3 (8): 62–64; discussion 64–65.

  17. R. Sitruk-Ware, “Progestins and Cardiovascular Risk Markers,” Steroids 2000 October-November; 65 (10–11): 651–658.

  18. P. Y. Scarabin, M. Alhenc-Gelas, G. Plu-Bureau, P. Taisne, R. Agher, and M. Aiach, “Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Blood Coagulation and Fibrinolysis in Postmenopausal Women: A Randomized Controlled Trial,” Arterioscler Thromb Vasc Biol 1997 November; 17 (11): 3071–3078.

  19. G. A. Colditz, “Hormones and Breast Cancer: Evidence and Implications for Consideration of Risks and Benefits of Hormone Replacement Therapy,” J Womens Health 1999 April; 8 (3): 354–357.

  20. F. Zhang, Y. Chen, E. Pisha, L. Shen, Y. Xiong, R. B. van Breemen, and J. L. Bolton, “The Major Metabolite of Equilin, 4-hydroxyequilin, Autoxidizes to an O-quinone Which Isomerizes to the Potent Cytotoxin 4-hydroxyequilenin-O-quinone,” Chem Res Toxicol 1999 February; 12 (2): 204–213.

  21. E. Pisha, X. Lui, A. I. Constantinou, and J. L. Bolton, “Evidence that a Metabolite of Equine Estrogens, 4-hydroxyequilenin, Induces Cellular Transformation in Vitro,” Chem Res Toxicol 2001 January; 14 (1): 82–90.

  22. F. Zhang, S. M. Swanson, R. B. van Breemen, X. Liu, Y. Yang, C. Gu, and J. L. Bolton, “Equine Estrogen Metabolite 4-hydroxyequilenin Induces DNA Damage in the Rat Mammary Tissues: Formation of Single-Strand Breaks, Apurinic Sites, and Stable Adducts, and Oxidized Bases,” Chem Res Toxicol 2001 December; 14 (12): 1654–1659.

  23. V. A. Tzingounis, M. F. Aksu, and R. B. Greenblatt, “Estriol in the Management of the Menopause,” JAMA 1978 April 21; 239 (16): 1638–1641.

  24. H. M. Lemon, P. F. Kumar, C. Peterson, J. F. Rodriguez-Sierra, and K. M. Abbo, “Inhibition of Radiogenic Mammary Carcinoma in Rats by Estriol or Tamoxifen,” Cancer 1989 May 1; 63 (9): 1685–1692.

  25. H. M. Lemon, H. H. Wotiz, L. Parsons, and P. J. Mozden, “Reduced Estriol Excretion in Patients with Breast Cancer Prior to Endocrine Therapy,” JAMA 1966 June 27; 196 (13): 1128–1136.

  26. H. M. Lemon, “Pathophysiologic Considerations in the Treatment of Menopausal Patients with Oestrogens: The Role of Oestriol in the Prevention of Mammary Carcinoma,” Acta Endocrinol Supplement 1980; 233: 17–27. DNH

  27. A. H. Follingstad, “Estriol: The Forgotten Estrogen,” JAMA January 2, 1978; 239 (1): 29–30.

  28. S. Kim, S. M. Liva, M. A. Dalal, M. A. Verity, and R. R. Voskuhl, “Estriol Ameliorates Autoimmune Demyelinating Disease: Implications for Multiple Sclerosis,” Neurology 1999 April 12; 52 (6): 1230–1238.

  29. S. Bansil, H. J. Lee, S. Jindal, C. R. Holtz, and S. D. Cook, “Correlation Between Sex Hormones and Magnetic Resonance Imaging Lesions in Multiple Sclerosis,” Acta Neurol Scand 1999 February; 99 (2): 91–94.

  30. L. D. Cowan, L. Gordis, J. A. Tonascia, and G. S. Jones, “Breast Cancer Incidence in Women with a History of Progesterone Deficiency,” Am J Epidemiol 1981 August; 114(2): 209–217.

  31. A. Inoh, K. Kamiya, Y. Fujii, and K. Yokoro, “Protective Effects of Progesterone and Tamoxifen in Estrogen-Induced Mammary Carcinogenesis in Ovariectomized W/Fu Rats,” Jpn J Cancer Res 1985 August; 76 (8): 699–704.

  32. M. Otsuki, H. Saito, X. Xu, S. Sumitani, H. Kouhara, T. Kishimoto, and S. Kasayama, “Progesterone, but not Medroxyprogesterone, Inhibits Vascular Cell Adhesion Molecule-1 Expression in Human Vascular Endothelial Cells,” Arterioscler Thromb Vasc Biol 2001 February; 21 (2): 243–248.

  33. H. A. Braunsberg, N. G. Coldham, and W. Wong, “Hormonal Therapies for Breast Cancer: Can Progestogens Stimulate Growth?” Cancer Lett 1986 February; 30 (2): 213–218.

  34. “Effects of Estrogen or Estrogen/Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women,” The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial, JAMA 1995 January 18; 273 (3): 199–208.

  35. News conference at the American Heart Association Annual Meeting, November 17, 1994.

  36. J. T. Hargrove et al., “Menopausal Hormone Replacement Therapy with Continuous Daily Oral Mircronized Progesterone,” Obstet Gyn 1989; 73: 606–612.

  37. J. T. Hargrove
and K. G. Osteen, “An Alternative Method of Hormone Replacement Therapy Using the Natural Sex Steroids,” Infertile Repro Med Clinics North Am. 1995; 6: 563–674. DNH

  38. J. T. Hargrove and E. Eisenberg, Menopause. Med. Clinics North Am 1995; 79: 1337–1356.

  39. H. M. Lemon, “Antimammary Carcinogenic Activity of 17-alpha-ethnyl Estriol,” Cancer 1987; 60: 2873–2881.

  40. J. Schneider, M. M. Huh, H. L. Bradlow, and J. Fishman, “Antiestrogen Action of 2-hydroxyestrone on MCF-7 Human Breast Cancer Cells,” J Biol Chem 1984; 259: 4840–4845.

  41. B. Vandewalle and J. Lefebvre, “Opposite Effects of Estrogen and Catechol Estrogen on Hormone-Sensitive Breast Cancer Cell Growth and Differentiation,” Mol Cell Endocrinol 1989; 61: 239–246.

  42. H. L. Bradlow, N. T. Telang, D. W. Sepkovic, and M. P. Osborne, “2-hydroxyestrone: The ‘Good’ Estrogen,” J Endocrinol 1996; 150: Supplement S259–S265.

  43. J. Fishman and C. Martucci, “Biological Properties of 16-alpha-hydroxyestrone: Implications in Estrogen Physiology and Pathophysiology,” J Clin Endocrinol Metab 1980; 51: 611–615. DNH

  44. J. Schneider, D. Kinne, A. Fracchia, V. Pierce, K. E. Anderson, H. L. Bradlow, and J. Fishman, “Abnormal Oxidative Metabolism of Estradiol in Women with Breast Cancer,” Proc Natl Acad Sci USA 1982; 79: 3047–3051.DNH

  45. M. P. Osborne, H. L. Bradlow, G. Y. C. Wong, and N. T. Telang, “Upregulation of Estradiol C16 Alpha-hydroxylation in Human Breast Tissue: A Potential Biomarker of Breast Cancer Risk,” J Natl Cancer Inst 1993; 85: 1917–1920.

  46. H. L. Bradlow, R. J. Hershcopf, C. P. Martucci, and J. Fishman, “Estradiol 16-hydroxylation in the Mouse Correlates with Mammary Tumor Incidence and Presence of Murine Mammary Tumor Virus: A Possible Model for the Hormonal Etiology of Breast Cancer in Humans,” Proc Natl Acad Sci USA 1985; 82: 6295–6299.

  47. N. T. Telang, A. Suto, G. Y. Wong, M. P. Osborne, and H. L. Bradlow, “Induction by Estrogen Metabolite 16 Alpha-hydroxyestrone of Genotoxic Damage and Aberrant Cell Proliferation in Mouse Mammary Epithelial Cells in Culture,” J Natl Cancer Inst 1992; 82: 634–638.

  48. G. C. Kabat, C. J. Chang, J. A. Sparano, D. W. Sepkovic, X. P. Hu, A. Khalil, R. Rosenblatt, and H. L. Bradlow, “Urinary Estrogen Metabolites and Breast Cancer: A Case-Control Study,” Cancer Epidemiol Biomark Prev 1997; 6: 505–509.